Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma

Giampaolo Talamo, Kevin L. Rakszawski, Witold Rybka, Nathan G. Dolloff, Jozef Malysz, Tamara Berno, Maurizio Zangari

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

High-dose melphalan (HD-Mel) is considered the current standard of care among the preparative regimens used in autologous peripheral blood stem cell transplantation (SCT) for multiple myeloma (MM), but optimal time and schedule of administration is not defined. We retrospectively analyzed outcomes and toxicities of HD-Mel administered on day -2 vs. day -1 before autologous stem cells infusion. A total of 138 consecutive MM patients treated at Penn State Hershey Cancer Institute between 2007 and 2010 were included in this study. No difference in time to hematopoietic recovery, common SCT-related toxicities, and clinical outcomes was seen between patients who received HD-Mel on day -2 (group A, n = 47), and those who received it on day -1 (group B, n = 91). Prompt and full hematopoietic recovery occurred even when stem cells were infused between 8 and 24 h after completion of chemotherapy. In the absence of prospective and randomized data, we conclude that a single I.V. infusion of HD-Mel on day -1 is a safe and effective practice, and the so-called 'day of rest' before the transplant appears not to be necessary.

Original languageEnglish (US)
Pages (from-to)145-150
Number of pages6
JournalEuropean Journal of Haematology
Volume89
Issue number2
DOIs
StatePublished - Aug 1 2012

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma'. Together they form a unique fingerprint.

  • Cite this